SCHEMBL719456

SCHEMBL719456

Nc1cc2c(cc1N)CCN(C(=O)C(F)(F)F)CC2

nearest known ligand 0.56

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 7/20 0.56
ESR2 Q92731 7/20 0.56
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA7 P43166 1/20 0.41
CA9 Q16790 1/20 0.41
HDAC6 Q9UBN7 2/20 0.39
ABHD6 Q9BV23 4/20 0.39
PKM P14618 1/20 0.38
HDAC8 Q9BY41 1/20 0.35
NR1H2 P55055 1/20 0.35
CYP11B2 P19099 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Water SCHEMBL3709828 0.97 ESR1 (0.54) ESR1ESR2CA12CA1CA2
Water SCHEMBL3709830 0.97 ESR1 (0.57) ESR1ESR2CA12CA1CA2
SCHEMBL2061259 0.85 ESR1 (0.55) ESR1ESR2CA1CA2CA7
SCHEMBL7421889 0.84 ESR1 (0.51) ESR1ESR2HDAC6ABHD6
SCHEMBL373718 0.83 ESR1 (0.58) ESR1ESR2CA12CA1CA2
SCHEMBL25226305 0.83 ESR1 (0.58) ESR1ESR2CA12CA1CA2
SCHEMBL31164724 0.83 ESR1 (0.62) ESR1ESR2CA12CA1CA2
SCHEMBL25204649 0.82 ESR1 (0.60) ESR1ESR2HDAC6ABHD6PKM
SCHEMBL30411869 0.82 ESR1 (0.60) ESR1ESR2HDAC6ABHD6PKM
SCHEMBL25205406 0.82 ESR1 (0.57) ESR1ESR2CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120053168-A1 FUSED BENZOAZEPINES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS TARGACEPT, INC. (US) 2012-03-01 US claimed
US-20120053168-A1 FUSED BENZOAZEPINES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS TARGACEPT, INC. (US) 2012-03-01 US disclosed
US-20120053168-A1 FUSED BENZOAZEPINES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS TARGACEPT, INC. (US) 2012-03-01 US disclosed
US-20120053168-A1 FUSED BENZOAZEPINES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS TARGACEPT, INC. (US) 2012-03-01 US disclosed
WO-2010096384-A2 FUSED BENZAZEPINES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS TARGACEPT, INC. (US) 2010-08-26 WO disclosed
WO-2010096384-A2 FUSED BENZAZEPINES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS TARGACEPT, INC. (US) 2010-08-26 WO disclosed
US-20090062257-A1 DEUTERIUM-ENRICHED VARENICLINE PROTIA, LLC (US) 2009-03-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053168-A1 FUSED BENZOAZEPINES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS CHRNA2, CHRNA5, CHRNA10 ESR1 1178/4885ESR2 825/4885CA12 4298/4885
US-20090062257-A1 DEUTERIUM-ENRICHED VARENICLINE DRD2, DRD1, DBH ESR1 3011/4885ESR2 2503/4885CA12 2583/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.